Jolanda Howe Sells 750 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 750 shares of the business’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $32,115.00. Following the completion of the sale, the senior vice president now owns 2,926 shares in the company, valued at approximately $125,291.32. This trade represents a 20.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Jolanda Howe also recently made the following trade(s):

• On Thursday, November 14th, Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.10, for a total transaction of $117,750.00.

Mirum Pharmaceuticals Stock Down 0.1 %

NASDAQ:MIRM opened at $42.00 on Thursday. The company has a market cap of $2.02 billion, a price-to-earnings ratio of -20.79 and a beta of 0.98. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $48.89. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a fifty day simple moving average of $42.86 and a 200-day simple moving average of $40.61.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.15. The company had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm’s revenue for the quarter was up 89.4% on a year-over-year basis. During the same quarter last year, the business posted ($0.57) EPS. Analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.46 EPS for the current year.

Institutional Trading of Mirum Pharmaceuticals

Large investors have recently modified their holdings of the company. Lord Abbett & CO. LLC purchased a new position in Mirum Pharmaceuticals during the 3rd quarter worth $28,913,000. Loomis Sayles & Co. L P purchased a new stake in shares of Mirum Pharmaceuticals in the 3rd quarter worth $19,473,000. Clearbridge Investments LLC grew its position in shares of Mirum Pharmaceuticals by 165.5% during the 2nd quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock worth $23,931,000 after buying an additional 436,349 shares in the last quarter. State Street Corp increased its stake in shares of Mirum Pharmaceuticals by 19.9% during the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock valued at $69,955,000 after buying an additional 297,511 shares during the period. Finally, Erste Asset Management GmbH bought a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at about $10,136,000.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on MIRM. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Leerink Partners increased their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. HC Wainwright reaffirmed a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Citigroup increased their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.